The Power of Telehealth and CGM Technology in Diabetes Management

By Staff Writer

November 14, 2023

The Rising Challenge of Telehealth and CGM Technology in Diabetes Management

As we celebrate World Diabetes Day, we must acknowledge the growing burden of diabetes care. With 37.3 million people in the United States diagnosed with diabetes, the healthcare industry faces a tremendous issue. The number of endocrinologists, or diabetes specialists, is frighteningly low, with a patient-to-endocrinologist ratio of 1:4375. Because of this imbalance, the majority of diabetes care is now provided in primary care settings. However, resources and expertise may be restricted in these settings. Telehealth and Continuous Glucose Monitoring CGM technology in diabetes management might enhance care for these patients in a significant way.

Continuous Glucose Monitoring (CGM) Technology’s Potential

CGM technology has demonstrated promising improvements in managing both type 1 and type 2 diabetes. CGM can lower haemoglobin A1c levels, enhance time in range (TIR) of 70 to 180 mg/dL, reduce the occurrence of hypoglycemia, and improve quality of life. Despite these advantages, however, CGM adoption is not prevalent, particularly in primary care settings.

 

The VDiSC (Virtual Diabetes Specialty Clinic)

The VDiSC, or virtual endocrinology clinic, was created to bridge the gap between an increasing number of diabetes patients and a limited number of endocrinologists. It employs telemedicine to deliver comprehensive diabetic treatment, facilitate CGM integration into diabetes self-management, and provide behavioral health support. This virtual model provides patients with type 1 and type 2 diabetes with access to specialised care without the need for actual travel, making it a more practical solution for individuals who live in rural places or have mobility concerns.

The JAMA study discovered that patients reported considerable benefits, including significant decreases in HbA1c levels and improvements in TIR. The VDiSC trial demonstrated that a virtual clinic care paradigm can deliver significant clinical advantages to diabetic patients. Telehealth services can potentially increase care access for everyone, reduce health inequities in communities, and aid in implementing breakthrough technology like CGM. The COVID-19 pandemic has made these services more accessible, showing promise for the management of chronic conditions like diabetes.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.